Compare · head to head
Dongwha Pharm vs Ilsung IS
Ilsung IS ranks higher overall — 360 rank 59 vs 44.
Dongwha Pharm leads on Growth (57 vs 48). Ilsung IS leads on Safety (50 vs 29) and Sentiment (59 vs 50). The two are close on Value and Quality.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | South Korea |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Small | Small |
| ISIN | KR7000020008 | KR7003120003 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 44 | 59 |
| Value | 55 | 51 |
| Quality | 51 | 50 |
| Growth | 57 | 48 |
| Safety | 29 | 50 |
| Sentiment | 50 | 59 |
| Quality details | ||
| Profitability | 68 | 47 |
| Cash Truth | 34 | 53 |
Dongwha Pharm vs Kukje PharmaDongwha Pharm vs Ildong HoldingsDongwha Pharm vs PharmGen ScienceDongwha Pharm vs Whanin PharmAdd a third stock →
Full analyses: Dongwha Pharm · Ilsung IS
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100